JP2009539961A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539961A5 JP2009539961A5 JP2009514901A JP2009514901A JP2009539961A5 JP 2009539961 A5 JP2009539961 A5 JP 2009539961A5 JP 2009514901 A JP2009514901 A JP 2009514901A JP 2009514901 A JP2009514901 A JP 2009514901A JP 2009539961 A5 JP2009539961 A5 JP 2009539961A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- cannabigerol
- pharmaceutically acceptable
- acceptable salt
- cannabigerovaline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QXACEHWTBCFNSA-SFQUDFHCSA-N Cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 7
- 239000011780 sodium chloride Substances 0.000 claims 7
- 230000002149 cannabinoid Effects 0.000 claims 6
- 229930003827 cannabinoid Natural products 0.000 claims 6
- 239000003557 cannabinoid Substances 0.000 claims 6
- 201000008895 mood disease Diseases 0.000 claims 5
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 claims 4
- 241000218236 Cannabis Species 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000000284 extract Substances 0.000 claims 3
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N Cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 2
- 229950011318 Cannabidiol Drugs 0.000 claims 2
- QHMBSVQNZZTUGM-MSOLQXFVSA-N Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-MSOLQXFVSA-N 0.000 claims 2
- 229940065144 cannabinoids Drugs 0.000 claims 2
- YJYIDZLGVYOPGU-XNTDXEJSSA-N 2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-XNTDXEJSSA-N 0.000 claims 1
- 206010002855 Anxiety Diseases 0.000 claims 1
- 206010057666 Anxiety disease Diseases 0.000 claims 1
- 206010033666 Panic disease Diseases 0.000 claims 1
- 210000003932 Urinary Bladder Anatomy 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 201000003104 endogenous depression Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007915 intraurethral administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 230000001575 pathological Effects 0.000 claims 1
- 239000000419 plant extract Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
Claims (15)
- ヒト患者における気分障害の治療のための医薬の製造における治療的有効量のカンナビゲロール、カンナビゲロバリン（cannabigerovarin）またはその医薬的に許容される塩の使用。
- 治療される気分障害が１以上の病的うつ病または臨床的うつ病；単極性気分障害；双極性気分障害；シンドローム性うつ病；パニック障害および不安である、請求項１記載の使用。
- 治療される気分障害がうつ病である、請求項２記載の使用。
- カンナビゲロール、カンナビゲロバリンまたはその医薬的に許容される塩が大麻植物からの抽出物である、請求項１〜３のいずれか記載の使用。
- 大麻植物からの抽出物がカンナビゲロール、カンナビゲロバリンまたはその医薬的に許容される塩と共抽出される全天然カンナビノイドおよび他の非カンナビノイド成分を含む、請求項４記載の使用。
- 大麻植物からの抽出物がカンナビゲロールリッチである、請求項４記載の使用。
- 大麻植物抽出物が総カンナビノイド含有量の80%(w/w)以上のカンナビゲロールを含む、請求項４記載の使用。
- カンナビゲロール、カンナビゲロバリンまたはその医薬的に許容される塩が単離されているか、または実質的に純粋である、請求項１〜３のいずれか記載の使用。
- 医薬が経鼻、舌下、口腔、局所、経口、直腸、静脈内、腹腔内、筋肉内、皮下、経皮、膣内、尿道内送達、噴霧器による送達、吸入蒸気としての送達または膀胱への導入による送達のために製剤化される、請求項１〜８のいずれか記載の使用。
- 医薬の単位投与形態が0.1〜1000 mgの量のカンナビゲロール、カンナビゲロバリンまたはその医薬的に許容される塩を含む、請求項１〜９のいずれか記載の使用。
- 医薬がさらに１以上のさらなるカンナビノイドを含む、請求項１〜１０のいずれか記載の使用。
- さらなるカンナビノイドがカンナビジオール（CBD）である、請求項１１記載の使用。
- さらなるカンナビノイドがカンナビクロメン（CBC）である、請求項１１記載の使用。
- カンナビゲロール、カンナビゲロバリンまたはその医薬的に許容される塩がカンナビゲロール（CBG）である、請求項１〜１３のいずれか記載の使用。
- カンナビゲロール、カンナビゲロバリンまたはその医薬的に許容される塩がカンナビゲロールプロピル類似体（CBGV）である、請求項１〜１４のいずれか記載の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81381406P | 2006-06-15 | 2006-06-15 | |
| US60/813,814 | 2006-06-15 | ||
| PCT/GB2007/002216 WO2007144628A1 (en) | 2006-06-15 | 2007-06-14 | Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009539961A JP2009539961A (ja) | 2009-11-19 |
| JP2009539961A5 true JP2009539961A5 (ja) | 2010-07-29 |
| JP5286255B2 JP5286255B2 (ja) | 2013-09-11 |
Family
ID=38353631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009514901A Active JP5286255B2 (ja) | 2006-06-15 | 2007-06-14 | カンナビゲロールを含有する医薬組成物のうつ病の治療のための使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8481085B2 (ja) |
| EP (1) | EP2037901B1 (ja) |
| JP (1) | JP5286255B2 (ja) |
| CA (1) | CA2655094C (ja) |
| WO (1) | WO2007144628A1 (ja) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2471190T3 (es) * | 2003-06-24 | 2014-06-25 | Gw Pharma Limited | Composiciones farmacéuticas que comprenden compuestos de tipo cannabicromeno |
| GB2450493A (en) * | 2007-06-25 | 2008-12-31 | Gw Pharma Ltd | Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors |
| GB2456183A (en) * | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| US20100293021A1 (en) * | 2009-01-23 | 2010-11-18 | Intranet Productivity Solutions, Ltd. | Method and system for task tracking and allocation |
| US8445034B1 (en) | 2010-11-02 | 2013-05-21 | Albert L Coles, Jr. | Systems and methods for producing organic cannabis tincture |
| US10045540B2 (en) | 2014-04-01 | 2018-08-14 | Fayetteville State University | Pest control composition |
| WO2015200049A1 (en) | 2014-06-26 | 2015-12-30 | Island Breeze Systems Ca, Llc | Mdi related products and methods of use |
| US20160298151A1 (en) | 2015-04-09 | 2016-10-13 | Sher Ali Butt | Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products |
| US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
| EP3478307A4 (en) | 2016-06-29 | 2020-02-26 | Cannscience Innovations Inc. | DECARBOXYLATED CANNABIS RESINS, USES AND METHODS OF MAKING |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| JP7225104B2 (ja) | 2017-02-01 | 2023-02-20 | ジービーエス グローバル バイオファーマ，インコーポレイテッド | マスト細胞関連炎症障害又は好塩基球媒介炎症障害の治療のためのカンナビノイド含有複合混合物 |
| US10272360B2 (en) | 2017-08-05 | 2019-04-30 | Priya Naturals, Inc. | Phytochemical extraction system and methods to extract phytochemicals from plants including plants of the family Cannabaceae sensu stricto |
| US20200405685A1 (en) * | 2017-12-08 | 2020-12-31 | Biotech Institute, Llc | High cannabigerol cannabis plants, methods of producing and methods of using them |
| US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
| US20230110830A1 (en) | 2018-04-09 | 2023-04-13 | Ellevet Sciences | Hemp extract for treatment of pain in animals |
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| AU2019371379A1 (en) * | 2018-10-31 | 2021-05-27 | Baymedica, Inc. | Cannabinoid analogs and methods for their preparation |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| JP2023503601A (ja) * | 2019-11-26 | 2023-01-31 | キャノピー グロウス コーポレイション | カンナビゲロール誘導体、およびカンナビノイド受容体モジュレーターとしてのその使用 |
| US11767306B2 (en) | 2020-01-17 | 2023-09-26 | Cannacraft, Inc | Methods for converting CBD to tetrahydrocannabinols |
| EP4121164A1 (en) * | 2020-03-17 | 2023-01-25 | Tauriga Sciences Inc. | Medicated cannabinoid compositions, methods of manufacturing, and methods of treatment |
| US11786838B2 (en) * | 2020-03-23 | 2023-10-17 | Cannacraft, Inc. | Methods for removing pesticides from Cannabis products |
| WO2022026613A2 (en) | 2020-07-28 | 2022-02-03 | Impello Biosciences, Inc. | Methods and compositions for altering secondary metabolites in plants |
| EP4271367A1 (en) | 2020-12-31 | 2023-11-08 | Cookies Creative Consulting & Promotions, Inc. | Compositions comprising cannabis and mushroom extracts, and uses thereof |
| US11465957B1 (en) * | 2021-04-08 | 2022-10-11 | MYKU Biosciences LLC | Methods and systems for crystallizing and isolating individual cannabinoids |
| US11345650B1 (en) | 2021-04-08 | 2022-05-31 | MYKU Biosciences LLC | Methods and systems for crystallizing and isolating individual cannabinoids |
| WO2023250274A1 (en) | 2022-06-22 | 2023-12-28 | Ilera Therapeutics Llc | Enhanced capture and dissolution matrix for cannabinoids and methods of making the same |
| WO2024015780A1 (en) | 2022-07-11 | 2024-01-18 | Ilera Therapeutics Llc | Zlt-007 and methods of treating diabetic neuropathy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002056932A2 (en) * | 2000-10-27 | 2002-07-25 | Emlin Biosciences | Thermal vaporizing device for drug delivery |
| GB2381450B (en) | 2001-10-31 | 2006-05-31 | Gw Pharma Ltd | Compositions for administration of natural or synthetic cannabinoids by vaporisation |
| EP1539069A4 (en) * | 2002-05-31 | 2007-11-14 | Univ Mississippi | TRANSMUCOSAL DELIVERY OF CANNABINOIDS |
| US6946150B2 (en) * | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
| GB0222077D0 (en) | 2002-09-23 | 2002-10-30 | Gw Pharma Ltd | Methods of preparing cannabinoids from plant material |
| ES2471190T3 (es) | 2003-06-24 | 2014-06-25 | Gw Pharma Limited | Composiciones farmacéuticas que comprenden compuestos de tipo cannabicromeno |
-
2007
- 2007-06-08 US US11/760,364 patent/US8481085B2/en active Active
- 2007-06-14 WO PCT/GB2007/002216 patent/WO2007144628A1/en active Application Filing
- 2007-06-14 EP EP07733222.9A patent/EP2037901B1/en active Active
- 2007-06-14 JP JP2009514901A patent/JP5286255B2/ja active Active
- 2007-06-14 CA CA2655094A patent/CA2655094C/en active Active
-
2013
- 2013-04-24 US US13/869,247 patent/US20140039043A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009539961A5 (ja) | ||
| US20090197941A1 (en) | Pharmaceutical Compositons for the Treatment of Chronic Obstructive Pulmonary Disease | |
| Zhang et al. | Erectile dysfunction and sexual hormone levels in men with obstructive sleep apnea: efficacy of continuous positive airway pressure | |
| UY26959A1 (es) | Nuevos polvos para inhalación que contienen tiotropio | |
| DK1715859T3 (da) | Fremgangsmåde til behandling og diagnosticering af åndedrætsforstyrrelser i sövnen ved hjælp af zonisamid og midler til at gennemföre fremgangsmåden | |
| JP2020524151A5 (ja) | ||
| Mei et al. | Antipyretic and anti-asthmatic activities of traditional Chinese herb-pairs, Ephedra and Gypsum | |
| JP2011500781A5 (ja) | ||
| NO20054767L (no) | Sammensetninger omfattende apomorfin for inhalering i lunge | |
| US11504350B2 (en) | Cannabinoid compositions and methods of use thereof | |
| JP2009537553A5 (ja) | ||
| AU2019225717B2 (en) | Genetically modified Cannabis sativa plants and modified cannabinoid compounds for treatment of substance addiction and other disorders | |
| WO2008022189A3 (en) | Administration of high potency platinum compound formulations by inhalation | |
| EA200701077A1 (ru) | Применение конъюгатов липидов при лечении заболеваний | |
| EP4027971A2 (en) | Orally dissolving mucoadhesive films utilizing menthol and l-arginine to enhance the bioavailability of cannabinoids | |
| ATE375146T1 (de) | Schleimdrogenbasierte lutschtablette gegen entzündliche erkrankungen des mund- und rachenraums | |
| WO2015135372A1 (zh) | 异佛司可林在防治慢性阻塞性肺病中的应用 | |
| EA201070336A1 (ru) | Ингаляционный азтреонам лизин для лечения нарушений, снижающих качество жизни, обусловленное состоянием здоровья при заболеваниях легких | |
| Yuan et al. | Protective effect of total flavones of rhododendra on ischemic myocardial injury in rabbits | |
| WO2015131655A1 (zh) | 佛司可林在防治慢性阻塞性肺病中的应用 | |
| JP2009525266A5 (ja) | ||
| WO2007046113A3 (en) | Novel pharmaceutical composition comprising alkaloid and process thereof | |
| US20210369802A1 (en) | Cannabis plant formulations and methods of delivery | |
| EP2570126B1 (en) | Use of melatonin for treating acute alcohol intoxication | |
| US20220168265A1 (en) | Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight |